PANTIPA: Preclinical development of patient-derived monoclonal antibodies targeting Pseudomonas aeruginosa
Pseudomonas aeruginosa is a bacterial pathogen that can cause life-threatening infections, such as sepsis and pneumonia. One of the key weapons used by this bacterium is the type III secretion system (T3SS), which contains the protein PcrV. Researchers at the DZIF discovered that chronically infected patients develop highly effective antibodies against PcrV. Building on this finding, the researchers produced monoclonal antibodies (mAbs) that block the T3SS and neutralize P. aeruginosa's virulence. The PANTIPA project aims to develop a patient-derived monoclonal antibody for the treatment of severe P. aeruginosa infections.
Following successful preclinical studies, UHC-D9b has been selected as the lead development candidate and is now entering the next stage of development, including process development and GMP-compliant manufacturing. The long-term goal is to develop UHC-D9b for two potential applications: the targeted treatment of acute P. aeruginosa infections, such as pneumonia or sepsis, and prophylactic use in particularly vulnerable patients through passive immunization.
The translational PANTIPA project receives special support as a DZIF flagship project. Learn more about PANTIPA and other DZIF flagship projects.